NCT00457197View on ClinicalTrials.gov

Quetiapine for Bipolar Disorder and Alcohol Dependence

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Bipolar DisorderAlcohol Dependence
Interventions
DRUG

Placebo

Inactive ingredient matching the active medication in appearance.

DRUG

Quetiapine

Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.

Trial Locations (1)

75235

Psychoneuroendocrine Research Program, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT00457197 - Quetiapine for Bipolar Disorder and Alcohol Dependence | Biotech Hunter | Biotech Hunter